BB Biotech (BION) Q4 2024 earnings summary

Executive summary

• 2024 marked the early stage of a structural recovery in biotech, with renewed investor focus on clinical data, regulatory approvals, and commercial execution.

• Net profit rebounded to CHF 76 mn in 2024 from a CHF 207 mn loss in 2023, despite continued sector volatility and a share price discount to NAV.

• The Board will propose a CHF 1.80 per share dividend, maintaining a 5% payout policy.

• Leadership transitions and team expansion, especially in the US, have strengthened analytical and operational capabilities.

• Portfolio companies achieved major clinical and regulatory milestones in Q4, validating the investment strategy.

Financial highlights

• 2024 share price total return: -13.5% in CHF, -14.1% in EUR; NAV up 3.0% in CHF, 1.7% in EUR; NBI Index up 7.6% in CHF.

• Q4 2024 share price return: -2.7% in CHF; NAV up 2.7% in CHF; net profit CHF 60 mn vs CHF 109 mn in Q4 2023.

• Share price traded at a 15.2% discount to NAV at year-end 2024, compared to a 0.9% premium at the start of the year.

Outlook and guidance

• Entered 2025 with positive momentum, supported by sector tailwinds and M&A activity, including J&J's USD 15 bn acquisition of Intra-Cellular Therapies.

• Anticipates significant product launches and clinical milestones in 2025, with a focus on high-impact innovation and expanding the portfolio toward 35 holdings.

• M&A activity expected to accelerate in 2025 as large biopharma seeks to replenish pipelines amid patent expirations.